Taaleri Oyj

Renewable And Bioindustry Trends Will Shape A Risky Future

AnalystConsensusTarget

Not Invested

Based on Analyst Price Targets

Published

11 Feb 25

Updated

01 May 25

Views

n/a

AnalystConsensusTarget's Fair Value

n/a

-4.1%

3.5%

-4.1%

3.5%

You can edit this narrative until May 12 6:00 AM. Then, changes will post as Updates.

Author's Valuation

€8.813.1% undervalued

AnalystConsensusTarget Fair Value

Narrative

Updates8

Shared on 01 May 25

Fair value Increased 3.90%

Shared on 23 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 17 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 09 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 02 Apr 25

Fair value Decreased 12%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 26 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 19 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 13 Mar 25

Fair value Increased 6.89%

AnalystConsensusTarget has decreased revenue growth from 0.7% to -4.9% and increased future PE multiple from 14.6x to 18.0x.

AnalystConsensusTarget Fair Value

€8.8

13.1% undervalued

Future estimation in

Growth p.a.

Decrease

Increase

Current revenue growth rate

0.41%

Capital Markets revenue growth rate

0.25%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

6.77%

Calculation

€21.86m

Earnings '28

13.19x

PE Ratio '28

€288.45m

Market Cap '28

€288.45m

Market Cap '28

28.00m

No. shares '28

€10.30

Share Price '28

€10.30 Share Price '28

Discounted to 2025 @ 6.68% p.a.

€8.49

Fair Value '25